It can be therefore speculated that the diagnostic specificity of sEV PD-L1 in pancreatic cancer would be potentially improved by combining tumor cell markers (e.g., GPC-1) or other molecules that co-expressed on PD-L1-positive sEVs. This evidence concerns the gene GPC1 and pancreatic neoplasm.